Puma Biotechnology Inc (NASDAQ:PBYI) price on current trading day, rose 19.40% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $3.57.
A look at the stock’s price movement, the level at last check in today’s session was $2.99. The PE ratio in trailing twelve months stood at 7.52. Turning to its 52-week performance, $7.15 and $2.22 were the 52-week high and 52-week low respectively. Overall, PBYI moved 16.29% over the past month.
Puma Biotechnology Inc’s market cap currently stands at around $175.24 million, with investors looking forward to this quarter’s earnings report slated for in March.
Wall Street analysts have also projected the company’s year-on-year revenue to grow to 220M, representing a -4.56% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that PBYI is a 50% Sell. On the other hand, the stock is on average a 50% Buy as suggested by medium term indicators while long term indicators are putting the stock in 50% Buy category.
1 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 0 analyst(s) rate the stock as a Hold, 1 recommend PBYI as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
PBYI’s current price about 23.41% and 19.16% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 72.21, while 7-day volatility ratio is 6.54% and 5.13% in the 30-day chart. Further, Puma Biotechnology Inc (PBYI) has a beta value of 1.35, and an average true range (ATR) of 0.20.
If we refocus on Puma Biotechnology Inc (NASDAQ:PBYI), historical trading data shows that trading volumes averaged 518.97K over the past 3 months. The company’s latest data on shares outstanding shows there are 49.07 million shares.
The 21.66% of Puma Biotechnology Inc’s shares are in the hands of company insiders while institutional holders own 54.44% of the company’s shares. Current price change has pushed the stock 17.05% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the PBYI stock continues to rise going into the next quarter.
